MBCI

Desktop Metal | August 12, 2021

Desktop Metal, Inc and The ExOne Company announced today they have entered into a definitive agreement pursuant to which Desktop Metal will acquire all of the issued and outstanding shares of ExOne common stock. Under the terms of the agreement, ExOne shareholders will receive $8.50 in cash and $17.00 in shares of Desktop Metal common stock for each share of ExOne common stock, for a total consideration of $25.50 per share, representing a transaction value of $575 million, subject to a collar me...

ABB | January 24, 2020

ABB is introducing 3D printing capabilities to its RobotStudio simulation and offline programming software, which will enable users to program ABB robots for additive manufacturing in just 30 minutes. Part of the PowerPac portfolio of RobotStudio, the new 3D Printing feature eliminates manual programming to allow faster prototype production. The 3D Printing PowerPac supports a variety of processes, such as welding and printing with granules or concrete and is ideal for low-volume, high-mix print...

Manufacturing Technology

Desktop Metal | October 07, 2021

As Desktop Metal continues to advance Additive Manufacturing 2.0 (AM 2.0) to reshape the future of manufacturing with mass production and turnkey AM solutions, the company is seeing growing European demand for metal binder jetting, including the Shop System™, the world’s first metal binder jetting system designed for machine shops. Since volume shipments of the Shop System began in the fourth quarter of 2020, the system has experienced strong adoption among leading glo...

VBI VACCINES | August 24, 2020

Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates. Therapure Biomanufacturing is an integrated contract development and manufacturing organization focused on biologic and high value therapeutics that can provide new options for patient care. Under this agreement, Therapure will be responsible for the biomanufacturing of the vaccine drug substance as wel...